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The advent and refinement of sequencing technologies has resulted in a decrease in both the cost and time needed to generate
data on the entire sequence of the human genome. This has increased the accessibility of using whole-genome sequencing and
whole-exome sequencing approaches for analysis in both the research and clinical contexts. The expectation is that more
services based on these and other high-throughput technologies will become available to patients and the wider population.
Some authors predict that sequencing will be performed once in a lifetime, namely, shortly after birth. The Public and
Professional Policy Committee of the European Society of Human Genetics, the Human Genome Organisation Committee on
Ethics, Law and Society, the PHG Foundation and the P3G International Paediatric Platform address herein the important issues
and challenges surrounding the potential use of sequencing technologies in publicly funded newborn screening (NBS)
programmes. This statement presents the relevant issues and culminates in a set of recommendations to help inform and guide
scientists and clinicians, as well as policy makers regarding the necessary considerations for the use of genome sequencing
technologies and approaches in NBS programmes. The primary objective of NBS should be the targeted analysis and
identification of gene variants conferring a high risk of preventable or treatable conditions, for which treatment has to start in
the newborn period or in early childhood.
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BACKGROUND
Next-generation sequencing technologies and genome sequencing
approaches: the reality and the potential
The development of next-generation sequencing (NGS) technologies
(ie, new high-throughput and massively parallel DNA sequencing
technologies) has substantially reduced both the cost and the time
required to sequence an entire human genome. The prospect of the
availability of NGS technologies and consequently the greater facility
to conduct whole-genome sequencing (WGS) have led some to predict
that the use of this technology will change the current practice of
medicine and public health by enabling more accurate, sophisticated
and cost-effective genetic testing.1 It is foreseen that in the short term,
the implementation of WGS in the clinic will improve diagnosis and
management of some disorders with a strong heritable component,2 as
well as improve personalized diagnosis and personalized drug therapy
and treatment. Presently, NGS is being used for targeted sequencing of
sets of genes to help guide cancer treatment, and a number of cancer
centers are considering using WGS or whole-exome sequencing
(WES) in the future. During pregnancy, noninvasive prenatal testing
for aneuploidy is also being done using NGS.3 In the clinic, WGS and
WES are also being used to identify the causes of rare genetic diseases
especially in children4 and in individuals with ‘atypical manifestations,
(that) are difficult to confirm using clinical or laboratory criteria alone,
or otherwise require extensive or costly evaluation’.5 Disorders for
which WGS has been used as a diagnostic tool are usually genetically
heterogeneous and have variable phenotypic expression such as
intellectual disability, congenital malformations and mitochondrial
dysfunctions.5 Other foreseen applications include tissue matching,
disease risk predictions, reproductive risk information, forensics or
even recreational genomic information (such as genealogy or non-
medically related traits). Nonetheless, Goldenberg and Sharp6 predict
that ‘it is likely that the earliest applications of whole-genome
sequencing will be restricted to settings in which genetic testing is
already a routine part of clinical or public health practice, such as state
newborn screening (NBS) programs’.6 In truth, it should be noted that
DNA testing, per se, is not a routine part of NBS and that only a very
small proportion of babies, depending on the country, have a DNA
test (as opposed to a biochemical test).7–9 Furthermore, the above
prediction could be criticized as the routine nature of NBS with its
often implied consent, together with its public health context, and the
particular vulnerability of the population tested, would make it an
unsuitable context into which to first welcome a WGS approach.
An important fact to keep in mind when discussing this topic and
reading through this document is that NGS and WGS are not
synonymous terms. NGS technologies are tools that can be used to
sequence DNA (and consequently analyze sequence variants), as well
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as to allow for the study of RNA and epigenetic phenomena. In this
article, we address the DNA sequencing capacity of NGS and
subsequent analysis. Furthermore, the use of such powerful high-
throughput sequencing technologies (whether they are the present
‘next/second generation’ or any future similarly functional version, ie,
third generation) does not dictate the amount of DNA to be
sequenced or how much of it will consequently be analyzed.
Admittedly, the sequencing approach can be determined by each
researcher or clinician. For instance, the entire genome or the entire
exome (protein coding regions) can be sequenced or one could decide
to only sequence targeted regions or genes of interest. Another
important point is that sequencing the entire genome or exome does
not necessarily mean that every single variant will ultimately be
analyzed; one can sequence the entire genome and then opt for
targeted analyses of only certain areas or genes. Herein, we use the
general term ‘genome sequencing’ to include any high-throughput
sequencing approach that offers the capacity to sequence large
amounts of DNA without specifying how much DNA is sequenced
or analyzed.
The goal of this statement is to analyze the relevant issues
specifically surrounding the potential use of genome sequencing in
publicly funded NBS programmes. The document culminates in a set
of recommendations to help inform and guide scientists and
clinicians, as well as policy makers regarding the necessary considera-
tions for the use of genome sequencing technologies in newborns.
This paper is the result of a collaboration between the members of
the Public and Professional Policy Committee of the European Society
of Human Genetics (ESHG), the Human Genome Organisation
Committee on Ethics, Law and Society, the PHG Foundation and
the P3G International Paediatric Platform. The first draft was written
and discussed by an editorial committee with representatives of the
various groups. The paper and recommendations were discussed in
the various groups and were posted on the ESHG website from 18
February 2014 until 13 March 2014 for public consultation. The final
version of the paper and recommendations were approved by the
ESHG Board and by the PHG Foundation in May 2014, and by the
HUGO Committee and the P3G International Paediatric Platform in
April 2014. The International Society for Neonatal Screening supports
the consideration of all issues raised in this paper and recommends
that it be used in guiding future debate on mutational analysis in NBS.
NBS and its expansion
NBS is a public health program aimed at the early identification in
asymptomatic newborns of conditions for which early and timely
interventions can lead to the elimination or reduction of associated
mortality, morbidity and disabilities. A test performed within a
screening program is not intended to be diagnostic; rather it aims to
identify individuals who are at sufficient risk to benefit from a referral
for diagnostic testing.10 Traditionally, only a few rare disorders
(eg, phenylketonuria or congenital hypothyroidism) were included
in the screening program. Based on the Wilson and Jungner11 criteria,
conventional neonatal screening programmes were limited to condi-
tions considered an important health problem, whose natural history
was well understood, required immediate medical intervention in
order to prevent serious and permanent illness, and for which
treatment was available. Based on this premise, NBS is usually
conducted without an explicit consent because NBS is seen to be in
the best interest of the child’s health and as a consequence is
considered as part of the routine care for newborns.
In recent years, the number of disorders offered on NBS panels has
increased in both North America and Europe.8,9,12 At present, NBS
programmes in the European Union (EU) are heterogeneous and aim
to identify between 1 and 30 treatable conditions.8 The diversity is
large; differences in the health-care systems’ structure, available funds,
local politics, input from professional groups, parent groups and the
general public has led to different approaches in the way screening
programmes have been set up, financed and governed. Confirmatory
diagnostics and follow-up show large discrepancies. DNA testing is
integrated as a final step in some programmes for cystic fibrosis
screening and usually less expensive tests (esp., tandem mass spectro-
metry) are used first.
Canada has no national strategy on NBS and there is a wide
variation between provincial programmes, including the number of
diseases for which screening is offered, the information given to
parents, consent and policies regarding the disclosure of carrier
status.13,14 In the United States, the Discretionary Advisory Committee
on Heritable Disorders in Newborns and Children currently recom-
mends 57 conditions for screening, including 31 core disorders and
26 secondary disorders,15 not all of which, as we briefly discuss below,
adhere to the classic Wilson and Jungner11 criteria. This evolution has
recently spurred controversy, with some critics arguing that the
proposed expansion of NBS is proceeding too rapidly and without
sufficient deliberation and care.16 It has been criticized for failing to
‘conform to contemporary standards of evidence-based decision-
making’.12 It has been advanced that the panel includes conditions
‘that do not urgently need treatment in the newborn period, or for
which no proven treatment is available, or for which the treatment is
much less significant and certain than the benefit of treatment for a
condition such as PKU’.17 This transformation has sparked debates on
the objectives and rationale of NBS, as well as the associated evaluative
and decision-making criteria.16,18,19
NBS and genome sequencing
In line with Goldenberg and Sharp’s6 prediction mentioned earlier,6 it
appears to be a common expectation that once sequencing techno-
logies are sufficiently robust and affordable, all newborns will have
(at least part of) their genomes sequenced at birth replacing current
tandem mass spectrometry used in NBS and potentially replacing any
additional genetic test that could be needed later in life. For a number
of reasons, this is not necessarily the best approach. As mentioned in a
recent European expert opinion document, the first condition the
authors recommend to be included in a NBS program is congenital
hypothyroidism.20 This is usually not a genetic condition and cannot
be diagnosed by genome sequencing. Therefore, for this condition, the
present NBS methods cannot be replaced by sequencing.21
Predictions have been made suggesting that the implementation of
sequencing technologies in newborns will become routine within a
decade, affecting future generations of newborns. A vision of how
newborns could be profiled was described over a decade ago in a UK
White Paper on genetics. The authors suggested that it might be
possible ‘to screen babies at birth’ and ‘to produce a comprehensive
map of their key genetic markers, or even their entire genome’.22 In
this way, ‘the baby’s genetic information could then be securely stored
on their electronic patient record for future use. It could then be used
throughout their lifetime to tailor prevention and treatment regimes to
their needs as further knowledge becomes available about how our
genes affect our risk of disease and our response to medicines’.22
Although there are presently practical, financial and ethical challenges
that make this vision difficult to achieve or even unlikely for some,
others, including Collins,23 believe that this is an inevitable end point
in the development of personalized medicine, based on the argument
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that such screening would allow the continuous integration of genetic
knowledge during the full length of our lives.
Importantly, it is also predicted that with the use of NGS, a greater
number of genetic variants causing pediatric diseases can be detected
‘without substantially increasing the costs of NBS’.6 When considering
NBS in general and more specifically the introduction of new
technologies and/or approaches, the issue of costs is not trivial.
Presently, the reported cost of the NBS procedure in 2011 in the
EU ranged from € 0.46 per newborn (Serbia; screening for two
conditions) to € 43.24 (the Netherlands; screening for 17 condi-
tions),20 while sequencing and analyzing the data is much more
expensive. Even when considering that Illumina recently announced
that it could finally deliver on producing the $1000 genome,24 this
price tag does not include the cost of managing or analyzing the data
or of the health-care professionals’ time to counsel and/or return
results. Admittedly, at the moment, evidence of the economic impact
of using WGS or other genome sequencing approaches in any context
is lacking, and the real costs of the entire process including storage of
data, data management and analysis, and return of results are, as of
yet, unknown.25 In fact, the general agreement that dealing with the
deluge of data generated from WGS or WES is far from an easy or
obvious task, has led some to specify ‘the $1000 genome’ and ‘the $100
000 analysis’.26 Therefore, the use of WGS or WES in NBS is not likely
to fit within the available public health-care budgets at present.
Furthermore, the interpretation of DNA data in a population of
healthy newborns is a challenge. The genotype–phenotype relationship
in metabolic conditions is often not straightforward. In the case of
Pompe disease, for instance, there is a large clinical diversity among
patients with the same genotype.27 Furthermore, the sensitivity of
sequencing analysis for specific disorders in each target population
should be carefully considered, as it may be lower compared with
present metabolic testing for some disorders. For instance, the current
screening strategy for cystic fibrosis is deemed to have a sensitivity of
over 95%. As not all disease-causing CFTR variants are known, the
genotype first approach might have a lower sensitivity, with a wide
variance in different populations. Also, the sequencing first approach
would identify not only affected children but also the carriers of a
combination of variants that might never cause a significant disease, or
for which genotype–phenotype correlations are lacking or
unsatisfactory.21 In this situation, there would be a concrete risk that
these children would be, nevertheless, considered ‘affected’ with the
potential consequences of overtreatment, as well as alterations in
family dynamics. An agenda for the responsible translation of genome
sequencing in NBS would include determining the prognostic value of
the variants identified.
A separate and equally important issue is the storage of large
amounts, potentially the entire genome’s worth, of sequence data. One
could argue that the genome of a newborn could be sequenced once,
and analysis later in life could focus on disorders relevant at that
(future) age. Storage of genetic information, however, raises a host of
questions, ranging from governance and privacy protection to ensur-
ing the stability and accessibility of the data.28,29 Furthermore, there is
the very real possibility that newer sequencing technologies that can
provide more complete and more accurate data more inexpensively
will emerge. Thus, it may be preferable to simply re-sequence
individuals when relevant, thereby removing many of the concerns
of storing the data (albeit this approach would also remove, to some
extent, the suggested advantage(s) of having the sequence ‘on hand’ to
serve in the larger framework of genomic or personalized medicine in
the future). Moreover, respect of newborns’ right to privacy, right not
to know and autonomy to give consent once they are of legal age also
suggests that storing the whole-genome sequence information for
further testing in childhood is premature. Nor is storage without
potential risk to privacy and confidentiality; it is becoming increasingly
evident that fully guaranteeing the anonymity of WGS data may be
impossible.30 Policy makers need to consider not only the information
content of the genome but also its role as a biometric that can be used
to identify and track individuals, and their relatives. Furthermore, the
costs of storing the data are unknown and may be high.
An additional relevant phenomenon when discussing the sequen-
cing of large portions of the genome, including WGS and WES, is that
of unsolicited findings. These are findings or results that are not
directly related to the scope of the initial research or clinical question(s).
Many different terms have been used to describe such findings,
including incidental findings, unanticipated findings and off-target
results.31 Despite the different (and potentially confusing) terms, they
are often used in this context to refer to unexpected findings that are
in some way ‘stumbled upon’ and/or a ‘surprise’ to the researcher or
clinician, unrelated to the initial reason for sequencing, and as such
raise questions about whether they should be returned to patients or
research participants. Unsolicited findings are not a phenomenon
restricted to genomics, they arise in clinical practice (eg, imaging) and
in other forms of biomedical research. They have, however, become a
focal point of debate in genomics owing to the fact that we can now
generate such large quantities of DNA almost all at once and thus have
access to much more data regardless of whether they are related to the
initial research or clinical question posed. In order to reduce the
chances of encountering unsolicited findings, authors suggest targeting
the sequencing and/or the DNA analysis to regions of the genome that
are directly relevant to the research question.32 Although this approach
will, indeed, help to avoid unsolicited findings, they cannot exclude
them entirely.
Even with these present challenges, the potential reality of using
NGS and WGS in NBS is drawing closer as revealed by the recent
funding (25 million USD over 5 years) by the National Institutes of
Health in the United States of America of various pilot projects that
will study the implications, challenges and opportunities associated
with the possible integration of genome sequencing in newborns.33
These projects aim to study different ways in which genome or exome
sequencing can be implemented in populations of newborns, for
example, one project will offer genome sequencing to asymptomatic
newborns, whereas another project aims to offer genome sequencing
to newborns who have symptoms and are being cared for in the
neonatal intensive care unit.34 These research projects may further
raise expectations about the use of high-throughput sequencing
technologies and genome sequencing in NBS. Now is the time to
consider what may be appropriate and anticipate developments while
closely monitoring developments in order to determine and clearly
describe whether and how genome sequencing may be used for
newborn populations. As indicated by the different approaches used in
these pilot projects, and keeping in mind that having access to new
tools that offer more possibilities, does not bind us to the imperative
of having to perform all that is possible simply because we can, it will
be essential for health-care systems to determine and clearly describe
whether and how NGS-based or genome sequencing is to be used for
newborn populations: should genome sequencing be used in NBS
programmes? If so, is it expected that genome sequencing will be used
as a first tier testing programme and as such will all babies,
automatically, (and by default) have specific regions or their whole-
genome sequenced and/or analyzed at birth?
Another use of genome sequencing in newborns would be for the
diagnosis of sick babies, however, as this does not fall under NBS and
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is ethically distinct from such programmes, it is beyond the scope of
this paper. Nevertheless, a similar dichotomy of approaches (screening
healthy children versus diagnosis of symptomatic children) has been
described by Wade et al35 regarding the use of WGS in pediatric
populations. Clearly, the approach chosen will depend on the
determined goal of the programme, and will have an important
impact on the resulting practical and ethical issues, including the
benefits and disadvantages of such a programme. As stated by Wade
et al,35 ‘Like most clinical tools, P-WGS (Pediatric whole-genome
sequencing) could be used for a range of purposes... Therefore,
meaningful assessment of P-WGS can be accomplished only when a
clear health care context has been specified, including the population
target and purpose of testing’.35 It should also be noted that screening
the entire population of newborns would not necessarily dictate the
number of conditions that would be studied; it could be decided to
study the same number of conditions presently offered at birth or it
could be decided to expand the panel of diseases even further. This
decision is obviously also very important and the debate over the
criteria or reasons to expand would, at present, to some extent, echo
the ongoing debate over expansion of NBS in the last decade, and we
do not offer herein a solution or recommendation regarding this
debate. Once the general approach of how to implement genome
sequencing in NBS is determined, programmes will still need to define
which conditions will be screened for and/or which results will be
returned.36 We stress that this discussion regarding which conditions
and which variants to include in the screening panel should be
discussed with all relevant stakeholders, including clinicians, research-
ers, ethicists, public health professionals, policy makers and patients
(or patient representatives).
NBS AND GENOME SEQUENCING: WHICH WAY FORWARD?
Should genome sequencing be used for NBS, a major expansion of
health information (including validated and non-validated, highly or
poorly predictive, more or less probabilistic and affecting mainly
adult-onset or childhood-onset conditions) and non-medical informa-
tion from an analysis of the sequence data might be generated
depending on how the sequence is analyzed. Despite the scientific
and public enthusiasm toward analyzing this wealth of information in
diagnostics, research and screening, this reality demands careful
appraisal with regard to the justification for using new sequencing
technologies and genome sequencing approaches, and the proportion-
ality of using them.37
Genome sequencing and NBS: a focused screening approach
Neonatal screening programmes have traditionally focused on dis-
orders with serious outcomes having accepted treatments, recognizable
latent or early symptomatic stages, a well-understood natural history, a
suitable test and an acceptable cost-benefit evaluation. It could be
possible to use new sequencing technologies as tools in NBS without
fundamentally changing this model. However, it is obvious that the
use of such tools (and any consequent sequencing approaches,
including WGS) has the potential to cause a paradigm shift in NBS.
As mentioned above, obtaining data on, and studying a restricted
number of genes and variants is a very different scenario than
generating data and studying the entire genome. With the present
capacity of producing a greater amount of data, it is essential that we
carefully consider our stance on the further expansion of the NBS
panel and therefore the discussion of the diseases to be included in
such a panel.
In general, for most common complex disorders, the genetic
variants that are currently understood constitute a relatively small
etiologic factor. Little evidence exists supporting the notion that the
use of WGS for common complex disorders will result in clinically
actionable information other than general health advice urging for a
healthy balanced diet, doing physical activity regularly and, in general,
abandoning unhealthy behavior.38 Although the focus on common
complex disorders in seeking to apply new genetic technologies to
public health is understandable, more might be gained by focusing on
rare disorders. Many individuals carry rare variants that might provide
preventive advantages if knowledge about their genetic risk was
available.
Therefore, in line with the original intention of NBS, the potential
application of new sequence technologies and genome sequence
approaches should have as their primary objective to focus on the
identification of highly penetrant disease-causing variants that confer a
high risk of preventable or treatable conditions during the newborn
and childhood period. As a consequence, this would include the
selection of variants and genes that clearly cause disease and are
known to have a high penetrance with effective and accepted
preventive or therapeutic interventions.39 This approach would thus
include the sequencing of targeted genes on a panel instead of
sequencing or analyzing the whole genome. In line with the view of
the International Society of Neonatal Screening, ‘screening tests should
not be recommended if indications of advantage from early diagnosis
are lacking or uncertain, or the test is unsuitable, or does not detect
those cases in which there might be an advantage’.40
Indeed, at the very least, the conditions included and returned to
parents at birth should offer clinical benefit in the near term, that is to
say during the newborn and childhood period. As stated by Caulfield
et al41 regarding the use of WGS in the clinic ‘Utility in a clinical
setting depends on many—and very different—factors, and must take
into account not only such performance characteristics as sensitivity,
specificity and positive and negative predictive value, but also
demonstration of beneficial impact of using the test on patients’
health, or on health services delivery. Failure to do so can trigger
overt harm to patients in addition to excessive cost to the healthcare
system’.41
Genome sequencing and NBS: evidence generation and responsible
cost appraisal
It still has to be proven whether the implementation of new
sequencing technologies and approaches in NBS would be an effective
public health strategy. Even if used in a targeted fashion, evidence will
have to be generated with regard to the development of a suitable test
(including the identification of the targeted variants), the targeted
conditions, the development of a calculation of costs and consequent
actual analysis of costs, the treatment pathways, the potential impact
on test recipients and the acceptability to the population. Moreover,
various other ethical, legal and social issues will also have to be
addressed before introduction.
Admittedly, in economic terms, the use of NGS as a screening tool
will only be cost effective when a certain minimum number of genetic
variants or genes are to be included. Also of note is the fact that if the
sequence generated at birth is to be used for further medical enquiries
throughout the individual’s lifetime, the economic evaluation of the
cost and benefit of using this technology and consequent sequencing
approaches becomes much more complicated than simply analyzing
the costs and benefits potentially incurred at birth and in early
childhood. The costs of storage of the data, its future or ongoing
interpretation, as well as the costs for follow-up or confirmatory
testing should be considered. Additional downstream costs to the
health-care system should also be considered. As explained by
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Andermann,19 ‘Although genetic services and screening programmes
aim to improve the health of the population, there is growing concern
that the increasing number of genetic tests becoming available at lower
costs could compromise the viability of the healthcare system. Even
though the tests themselves may be inexpensive and suitable for large-
scale use, the infrastructure and human resources needed to provide
appropriate education, counseling, interventions and follow-up are
likely to be far more costly. When it comes to the allocation of scarce
resources, economic considerations must be considered alongside
‘notions of justice, equity, personal freedom, political feasibility, and
the constraints of current law’.19
Genome sequencing and NBS: focus on the best interests of the
child
Debates on the remit of NBS must also confront differing interpreta-
tions of what constitutes the ‘benefits’ of NBS: from what is good for
the infant to what might be potentially good for the infant, to what
might be good for the family (eg, reproductive benefit or health
benefits for family members) or to what, currently, might be beneficial
for society at large (eg, for research).42
Although NBS might indeed lead to the identification of informa-
tion that is relevant for the parents (eg, carrier status), the primary
justification of doing neonatal screening should be the health interests
of the child. From this perspective, the goal should not be in the
purposeful identification of information beyond the primary goal of
the screening. However, if the detection of an unsolicited genetic
variant would be indicative of serious health problems in the minor
that allows for treatment or prevention, a health-care professional
should report such variants.37 Furthermore, parents may also be
offered information regarding unsolicited findings that are severe and
clinically actionable relevant to their own health. This occasion will
likely arise rarely as laboratories will rarely find or ‘stumble upon’
additional predisposing variants in the process of analyzing the genes
targeted by NBS programmes. The authors strongly recommend that
laboratories should not examine genes beyond those targeted in
screening.
Any approach to screen newborns using genome sequencing should
be coherent with general principles regarding genetic testing in
children. ‘There has been a longstanding consensus that the primary
and strongest justification for genetic testing of children exists when
the results will clarify the cause of current symptoms, when the onset
of the condition may occur during childhood, or when the informa-
tion will be used to embark on a course of care that must start during
childhood to prevent or ameliorate later symptoms’.43 A major
rationale behind this position is that testing in children should be
delayed until the person is old enough to make an informed choice. In
clinical care, this reflects the careful consideration that is currently
given through pretest genetic counseling, where special attention is
paid to the transfer of information about the test and the test results,
the confidentiality of genetic information, the voluntariness of the
request, the responsibility toward blood relatives and the psychological
impact of a test.
Genome sequencing and NBS: informed consent
NBS is usually conducted without explicit consent because it is
considered to be in the best interest of the child’s health and, as a
consequence, part of routine pediatric care for newborns. Various
studies reported that many parents experienced NBS as a largely
routine practice and felt uninformed about the procedure.44 In
reaction to this, efforts were made to inform parents about the
disorders screened and the potential consequences of the screening.45
Most consider this model of presumed consent to be an appropriate
approach in the context of NBS for conditions that provide clear
evidence of medical benefit for the newborns. Concerns have been
raised that a model of explicit consent could lead to a reduced uptake
in screening,46 although there is little evidence to support this. If
genome sequencing is used in the context of NBS, new models of
informed consent in the context of NBS will have to be developed that
on the one hand increase the information provided and ensure it is
provided at the right time,47 and on the other hand maximize
participation rates, as the main focus of NBS should be finding the
at-risk asymptomatic child for whom prevention or treatment is
available during childhood. Furthermore, another important con-
sideration is the amount of time a health-care professional will need to
communicate the necessary information and obtain informed consent.
The potential need for (more) time and resources for consent should
also be considered in light of the suggestion that before testing, parents
be made aware of the possibility of generating unsolicited finding.
Genome sequencing and NBS: storage of sequence data and samples
for research
Samples from NBS are usually stored in public health laboratories in
order to permit diagnosis, re-testing to confirm results, postmortem
diagnosis, and for laboratory audit and quality control. The short-term
storage of these samples for these purposes is generally not particularly
controversial, as these uses are related to the primary purpose of the
initial collection. However, the issue of storage of NBS samples for a
longer term has become an important matter of debate.48 The
potential generation of sequencing data in the NBS context and the
storage of residual NBS biological material would clearly provide
opportunities for research that might contribute significantly to health.
However, given the particular sensitivity of the governmental context
of NBS programmes, such storage would only be possible with well
elaborated explicit consent procedures and adequate privacy and
confidentiality procedures.
Genome sequencing and NBS: use of sequence data in the clinical
file
Careful considerations will have to be made about who would
undertake and be responsible for the potential further analysis of this
sequence data and deciding what will be kept in the medical record.
The need for better education and training of health-care professionals
has been raised as an important goal as we prepare for a health-care
setting where genomic medicine is expected to have an increasingly
larger role. The question about whether clinicians will be able to
interpret the copious amounts of data generated by genome sequen-
cing, including WGS and WES,6 and how we can ensure that they are
properly trained to do so is of fundamental importance.49 This will
become more and more important if genome sequencing is to be used
in the newborn period and if sequence data is to become part of the
medical file (even if some parts would not have been analyzed at birth,
but would be used at specific moments in time, for instance, at
reproductive age).28 A clear protocol for the safe storage of the data in
electronic medical files should be elaborated. The analyzed results as
well as unanalyzed data should be handled and treated like all clinical
information included in patients’ medical file, and be protected by
adequate privacy and confidentiality procedures.
Genome sequencing and NBS outside public health programmes
A relevant point to keep in mind in the discussion of using genome
sequencing in newborns is the fact that private companies outside of
the public health-care system are currently offering WGS to
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consumers. As such, this could be a way for parents to have their
child’s DNA sequenced at any stage of life, regardless of what the
traditional public health-care screening context offers.50 As with the
ongoing discussion about genetic testing offered direct-to-consumer,
this fact raises the question of whether any other form of regulation
and/or guidance may be needed for genetic services offered outside the
traditional health-care system.51 As commercial offers of genome
sequencing might affect the public health-care system and various
ethical concerns are similar whether genome sequencing is happening
in a private setting or as part of a public health context, the reflections
and recommendations developed in this document apply in both
settings.
CONCLUSION
For more than four decades, NBS programmes have been set up
worldwide in order to identify infants for whom early treatment or
preventive actions would provide a clear health benefit to the child.
The discussion regarding the use of next-generation technology as a
tool or the use of genome sequencing approaches in NBS raises
questions about a possible paradigm shift in health care: will we use
new sequencing technologies as a tool to answer focused clinical
questions or will we use it to sequence entire genomes in order to
return a set of results at birth and as a pure data and information
generator, much of which can be analyzed and returned throughout a
person’s lifetime? The first approach raises differences in scale but is
amenable to our current forms of analysis such as cost effectiveness
and evaluation of population health programmes and so on. The
second approach is partially based on an assumption that personalized
medicine based on analysis of the genome is a potential reality,
desirable and an effective use of scarce health-care resources.
The availability of NGS technologies creates high expectations
regarding the potential of these technologies in the context of NBS.
However, the potential implementation of genome-sequencing tech-
nologies in NBS will take years and will necessitate further societal and
professional debate on the desired aims of neonatal screening with a
wide variety of stakeholders involved.36 Indeed, there is still much to
be learned in terms of science as well as the ethical, legal and social
issues regarding the use of new sequencing technologies and genome
sequencing approaches in health-care and public health programmes;
we should avoid hasty action and untimely application of these tools
and approaches in NBS programmes.
It should be noted that during the public consultation process in the
preparation of this document, some NBS and/or genome sequencing-
related issues were raised by various stakeholders that merit further
attention but unfortunately extend beyond the scope of this article.
These include the discussion of the role that policy makers may have
in considering the implications of integrating genome sequencing into
NBS as well as more fundamental issues related to the public (mis)
understanding of the role of genetics in determining health status,
impact on insurability, the discussion of genomic sequencing in NBS
within the wider context of genomic sequencing for prenatal (non-
invasive) screening or preconceptual carrier screening, and how such
screening programmes may impact upon society’s view and under-
standing of health, and the potential inequalities between countries
that can afford to use genomic technologies and those that cannot.
Although we cannot address all of these issues herein, we hope that
this document will help initiate further discussion and research
regarding these important issues.
Finally, the recommendations proposed in this statement provide a
first orientation in the debate on the potential implementation of
genome sequencing in NBS.
RECOMMENDATIONS
NGS technologies are powerful tools that allow for novel approaches
for studying the genome, including generating the entire nucleotide
sequence of an individual. With respect to this capacity to study DNA
variants in relation to disease, it can be used at different stages of life,
including at birth. The following recommendations are not meant as
an encouragement to use new sequencing tools or genome sequencing
approaches in NBS programmes, but rather they offer a list of areas
that must be carefully addressed should stakeholders consider using
said technologies and approaches in NBS programmes. Furthermore,
before such tools and approaches are introduced into NBS pro-
grammes, the goals and values of these programmes should be
explicitly articulated. The responsible use of genome sequencing
within a public health programme such as NBS should not be
technology driven, but rather be adopted on the basis of its public
health potential. The primary justification for performing genome
sequencing within the context of NBS should be the health interests of
the child. We recommend that the following issues be addressed when
considering whether genome sequencing be incorporated into NBS
programmes.
Purpose
The primary objective of genome sequencing in NBS should be the
identification of gene variants conferring a high risk of preventable or
treatable conditions, for which treatment has to start in the newborn
period or in early childhood. This includes the selection of variants
that clearly cause disease, are known to have high penetrance, and for
which effective and accepted preventive therapeutic interventions are
available. At this time, we recommend a targeted sequencing or
targeted analysis approach.
Evidence
A robust evidence base is a prerequisite for responsible and effective
NBS. This evidence base requires the understanding of the presence of
variants in certain populations, the sensitivity and specificity of tests,
the identification of treatment pathways or preventive action, the
calculation of immediate and downstream costs, the assessment of
lives saved, quality of life gained and the potential impact on families,
and, finally, the determination of public acceptability.
Costs
The infrastructure and human resource costs to ensure monitoring,
appropriate education, counseling, interventions and storage must be
assessed. Appropriate studies should be undertaken to obtain a realistic
picture of all costs involved as part of NBS in a public health
programme, including subsequent diagnostic costs as well as the costs
of not implementing genome sequencing.
Engagement
The perception of the harm and benefits of screening is very different
among different stakeholders. For this reason, it is important to have
an open dialogue about the expected medical and social benefits with
all stakeholders, including patients and their representatives, and the
general public. Moreover, governments should engage with key
opinion leaders to establish sound policy to guide any integration of
genome sequencing into NBS. This would enable a population health
approach to be followed, key frameworks to be developed, support
decision making in relation to the conditions for which screening
could be offered and would support a consistent approach between
jurisdictions within a region.
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Informing parents
Even if only targeted genome sequencing is adopted, new NBS
models of informing parents will have to be developed. They
should provide the necessary information but also maximize
participation rates as the main focus of NBS should always be the
identification and treatment of the asymptomatic, at-risk newborn.
These should also include information about the possibility of
finding unsolicited results, potential storage and research uses of
the samples and data.
Educating professionals and the public
Attention should be paid to the particular education and training
needs of the health-care professionals involved in NBS. This includes
the development of public education programmes to increase public
understanding of both genomics and NBS, their benefits and
limitations.
Future uses beyond NBS
Storing the whole-genome sequence or large amounts of sequence
information of newborns for health-care purposes is premature at this
time. Policy makers need to consider uses to improve public health
and research, as well as their potential to identify individuals and their
relatives.
Unsolicited findings
An approach using a targeted sequencing or targeted analysis will likely
limit the number of unsolicited findings. However, unsolicited
findings indicative of serious health problems for the child should
still be reported to parents where treatment or prevention is available
during childhood. Moreover, as carrier status information may be
relevant to parents for reproductive choices, they could be offered this
information. Parents may also be offered information regarding
unsolicited findings that are severe and clinically actionable relevant
to their own health.
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